Zoar Limited completed its business combination on November 17, 2026, combining with Impact Biomedical and acquiring all issued and outstanding shares of Zoar Labs from its sole shareholder, Dr. Kanans Visvanats, in exchange for Zoar ordinary shares. Impact survived as a wholly owned subsidiary, renamed Zoar USA Inc., and each Impact common share was converted into the right to receive one Zoar ordinary share. Zoar shares were expected to begin trading on NYSE American under ZOAR on November 18, 2026.
For the fiscal year ended March 31, 2026, Zoar Labs reported revenue of $651.7 million, up approximately 17.1% from $556.4 million in the prior fiscal year, and net income of $77.7 million, up approximately 23.9% from $62.7 million. Following the transaction, Zoar had approximately 180.0 million ordinary shares outstanding; Dr. Visvanats held approximately 93.32% and former Impact stockholders held approximately 4.80%. Zoar develops and manufactures active pharmaceutical ingredients and intermediates and provides contract development and manufacturing services. Its products are sold to customers in over 35 countries.